Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | STK10 | O94804 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837855 | 0.89 | GRM5 (0.48) | GRM5NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL3839765 | 0.83 | GRM5 (0.47) | GRM5NPC1RAB9AALDH1A1 | |
| SCHEMBL3836693 | 0.83 | GRM5 (0.47) | GRM5POLB | |
| SCHEMBL3836423 | 0.78 | GRM5 (0.58) | GRM5NPC1RAB9A | |
| SCHEMBL3837282 | 0.78 | GRM5 (0.58) | GRM5NPC1RAB9A | |
| SCHEMBL3836422 | 0.78 | GRM5 (0.58) | GRM5NPC1RAB9A | |
| SCHEMBL5130933 | 0.77 | GRM5 (0.54) | GRM5NPC1RAB9AALDH1A1 | |
| SCHEMBL3835800 | 0.75 | GRM5 (0.45) | GRM5 | |
| SCHEMBL3835093 | 0.74 | GRM5 (0.44) | GRM5NPC1RAB9A | |
| SCHEMBL3835814 | 0.73 | GRM5 (0.50) | GRM5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877367-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | claimed |
| EP-1877367-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20080194551-A1 | Acetylene Derivatives | NOVARTIS PHARMA GMBH (AT) | 2008-08-14 | — | — | US | disclosed |
| EP-1877367-A1 | ACETYLENE DERIVATIVES | Novartis AG (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114264-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194551-A1 | Acetylene Derivatives | NAT1, B3GNT2, NAT10 | GRM5 3731/4885NPC1 211/4885RAB9A 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.